REFERENCES
1. International Diabetes Federation. Diabetes atlas IDF. 10th ed. International Diabetes Federation; 2021.
2. Global report on diabetes. Geneva: World Health Organization, 2016.
3. American Diabetes Association; 11. Microvascular complications and foot Care: Standards of medical care in diabete-2020. Diabetes Care. 2020; 43 (Suppl 1): 135–51. DOI: https://doi.org/10.2337/dc20-S 011
4. Ziegler D., Papanas N., Vinik A.I., et al. Epidemiology of polyneuropathy in diabetes and prediabetes. Handb Clin Neurol. 2014; 126: 3–22. DOI: https://doi.org/10.1016/B 978-0-444-53480-4.00001-1
5. Ziegler D., Tesfaye S., Spallone V., Gurieva I., et al. Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations, Diabetes Res Clin Pract. 2022; 186:109063. DOI: https://doi.org/10.1016/j.diabres.2021.109063
6. Pop-Busui R., Ang L., Boulton A.J.M. Diagnosis and Treatment of Painful Diabetic Peripheral Neuropathy. American Diabetes Association. Nevro. 2022; (1): 1–32.
7. Callaghan B.C., Little A.A., Feldman E.L., et al. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012; (6): CD 007543,
8. Dluhy R.G., McMahon G.T. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008; 358 (24): 2630–3.
9. Strokov I.A., Manukhina E.B., Bakhtina L. Yu. The state of endogenous protective systems in patients with insulin-dependent diabetes mellitus with polyneuropathy: the effect of antioxidant therapy. Bull experiment biol and medical. 2000; 130 (10): 437–41. (in Russian)
10. Ziegler D., Nowak H., Kempler P., et al. Treatment of symptomatic diabetic polyneuropathy with antioxidant α-lipoic acid: a meta-analysis. Diabet Med. 2004; (21): 114–21.
11. Strokov I.A., Melnichenko G.A., Albekova Zh.S. Prevalence and risk factors for the development of diabetic polyneuropathy in hospitalized patients with type 1 diabetes mellitus. Nervno-myšečnye bolezni [Neuromuscular Diseases]. 2012; 1: 25–31. (in Russian)
12. Ziegler D., Ametov A., Barinov A. et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 trial. Diabetes Care. 2006; 29 (11): 2365–70.
13. Hicks C.W., Selvin E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr Diab Rep. 2019; 19 (10): 86.
14. Ziegler D., Low P.A., Boulton A.J.M. Effect of a 4-year antioxidant treatment with alpha-lipoic acid in diabetic polyneuropathy: the NATHAN-1 trial. Abstract 0007-OR, presented at 67th ADA Congress, Chicago, 22–26 June, 2007.
15. Dyck P.J. Detection, characterization and staging of polyneuropathy: assessed in diabetics. Muscle Nerve. 1988; 11 (1): 21–32.
16. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005; 54 (6): 1615–25.